Coherus BioSciences (CHRS) Misses Q4 EPS by 19c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Nasdaq futures slip on chip weakness; S&P 500 holds gains
- Massive market rotation raises question: Is the sell-AI trade here to stay?
- Goldman sees major AI and data center policy implications from ‘blue tsunami’
- Nvidia chips stockpile in Hong Kong awaits China import approval - report
- Goldman says this FX trade is the best hedge for the AI drawdown
Tweet
Share
E-mailGet Alerts CHRS Hot Sheet
Price: $0.85 --0%
EPS Growth %: +39.4%
Financial Fact:
Other income: 348K
Today's EPS Names:
KEEL, SENEA, XFOR, More
EPS Growth %: +39.4%
Financial Fact:
Other income: 348K
Today's EPS Names:
KEEL, SENEA, XFOR, More
Join SI Premium – FREE
Coherus BioSciences (NASDAQ: CHRS) reported Q4 EPS of $0.53, $0.19 worse than the analyst estimate of $0.72. Revenue for the quarter came in at $123.9 million versus the consensus estimate of $123.01 million.
For earnings history and earnings-related data on Coherus BioSciences (CHRS) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Appian Corporation (APPN) Tops Q3 EPS by 18c; Offers Guidance
- Arrow Electronics (ARW) Tops Q3 EPS by 147c ; Offers Guidance
- Nextdoor Holdings, Inc. (NXDR) reported Q3 Revenue ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
